#Rubella

A new study from the Institute of Science and Technology Austria (ISTA) introduces a brain organoid model that includes microglia, the brain’s immune cells. This addition enhances the model’s ability to simulate inflammation and improves prospects for safer pharmaceutical testing during pregnancy. The development is timely for global health and aligns with Thai prenatal care policy ambitions to refine safe medication guidelines for expectant mothers.

Historically, brain organoid models lacked microglia, limiting their accuracy in mimicking how the human brain responds to infections. By incorporating microglia, researchers can better understand how the developing nervous system reacts to infections such as Rubella, a concern for pregnant women due to potential fetal complications. In Thailand, where maternal and neonatal health remains a policy priority, this research supports national efforts to reduce congenital risks and strengthen prenatal care.

In a groundbreaking study from the Institute of Science and Technology Austria (ISTA), researchers have developed an advanced brain organoid model that incorporates microglia—special cells that play a crucial role in monitoring and maintaining brain health, particularly during inflammatory responses. This development holds potential for transforming pharmaceutical testing, especially concerning drug safety for pregnant women. Given the absence of specific antiviral treatments for conditions like Rubella during pregnancy, this advancement is noteworthy for both local and global health communities.